Implanon patents expiration

IMPLANON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant
Aug, 2026

(2 years from now)

US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(3 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(3 years from now)

US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(6 years from now)

Implanon is owned by Organon.

Implanon contains Etonogestrel.

Implanon has a total of 4 drug patents out of which 0 drug patents have expired.

Implanon was authorised for market use on 17 July, 2006.

Implanon is available in implant;implantation dosage forms.

Implanon can be used as prevention of pregnancy.

The generics of Implanon are possible to be released after 28 July, 2030.

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy


More Information on Dosage

IMPLANON family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic